114 related articles for article (PubMed ID: 37806183)
21. The Profile of MicroRNA Expression and Potential Role in the Regulation of Drug-Resistant Genes in Doxorubicin and Topotecan Resistant Ovarian Cancer Cell Lines.
Stasiak P; Kaźmierczak D; Jopek K; Nowicki M; Rucinski M; Januchowski R
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628654
[TBL] [Abstract][Full Text] [Related]
22. Expression of Osteoblast-Specific Factor 2 (OSF-2, Periostin) Is Associated with Drug Resistance in Ovarian Cancer Cell Lines.
Sterzyńska K; Kaźmierczak D; Klejewski A; Świerczewska M; Wojtowicz K; Nowacka M; Brązert J; Nowicki M; Januchowski R
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31412536
[TBL] [Abstract][Full Text] [Related]
23. Myotilin, a New Topotecan Resistant Protein in Ovarian Cancer Cell Lines.
Sterzyńska K; Klejewski A; Wojtowicz K; Świerczewska M; Nowicki M; Brązert J; Januchowski R
J Cancer; 2018; 9(23):4413-4421. PubMed ID: 30519347
[No Abstract] [Full Text] [Related]
24. Topotecan as a molecular targeting agent which blocks the Akt and VEGF cascade in platinum-resistant ovarian cancers.
Tsunetoh S; Terai Y; Sasaki H; Tanabe A; Tanaka Y; Sekijima T; Fujioka S; Kawaguchi H; Kanemura M; Yamashita Y; Ohmichi M
Cancer Biol Ther; 2010 Dec; 10(11):1137-46. PubMed ID: 20935474
[TBL] [Abstract][Full Text] [Related]
25. Microarray-based detection and expression analysis of extracellular matrix proteins in drug‑resistant ovarian cancer cell lines.
Januchowski R; Zawierucha P; Ruciński M; Zabel M
Oncol Rep; 2014 Nov; 32(5):1981-90. PubMed ID: 25199881
[TBL] [Abstract][Full Text] [Related]
26. [The mechanism of topotecan resistance in ovarian cancer cell line].
Jia P; Wu SB; Li F; Xu Q; Wu MF; Liao GN; Lu YP; Ma D
Zhonghua Zhong Liu Za Zhi; 2004 Mar; 26(3):139-42. PubMed ID: 15196431
[TBL] [Abstract][Full Text] [Related]
27. Breast cancer resistance protein-mediated topotecan resistance in ovarian cancer cells.
Jia P; Wu S; Li F; Xu Q; Wu M; Chen G; Liao G; Wang S; Zhou J; Lu Y; Ma D
Int J Gynecol Cancer; 2005; 15(6):1042-8. PubMed ID: 16343180
[TBL] [Abstract][Full Text] [Related]
28. The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel.
Ahmed AA; Mills AD; Ibrahim AE; Temple J; Blenkiron C; Vias M; Massie CE; Iyer NG; McGeoch A; Crawford R; Nicke B; Downward J; Swanton C; Bell SD; Earl HM; Laskey RA; Caldas C; Brenton JD
Cancer Cell; 2007 Dec; 12(6):514-27. PubMed ID: 18068629
[TBL] [Abstract][Full Text] [Related]
29. The significance of interferon gamma inducible protein 16 (IFI16) expression in drug resistant ovarian cancer cell lines.
Borucka J; Sterzyńska K; Kaźmierczak D; Świerczewska M; Nowacka M; Wojtowicz K; Klejewski A; Nowicki M; Zabel M; Ramlau R; Januchowski R
Biomed Pharmacother; 2022 Jun; 150():113036. PubMed ID: 35489285
[TBL] [Abstract][Full Text] [Related]
30. Gene Expression Indicates Altered Immune Modulation and Signaling Pathway Activation in Ovarian Cancer Patients Resistant to Topotecan.
Menyhárt O; Fekete JT; Győrffy B
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31195594
[TBL] [Abstract][Full Text] [Related]
31. Novel ABCG2 Antagonists Reverse Topotecan-Mediated Chemotherapeutic Resistance in Ovarian Carcinoma Xenografts.
Ricci JW; Lovato DM; Severns V; Sklar LA; Larson RS
Mol Cancer Ther; 2016 Dec; 15(12):2853-2862. PubMed ID: 27671528
[TBL] [Abstract][Full Text] [Related]
32. [Antisense oligonucleotide reverses topotecan-resistant ovarian cancer cells].
Jia P; Wu SB; Xu Q; Wu MF; Gao QL; Liao GN; Lu YP; Ma D
Ai Zheng; 2003 Dec; 22(12):1296-300. PubMed ID: 14693055
[TBL] [Abstract][Full Text] [Related]
33. Tumor-associated macrophages promote ovarian cancer cell migration by secreting transforming growth factor beta induced (TGFBI) and tenascin C.
Steitz AM; Steffes A; Finkernagel F; Unger A; Sommerfeld L; Jansen JM; Wagner U; Graumann J; Müller R; Reinartz S
Cell Death Dis; 2020 Apr; 11(4):249. PubMed ID: 32312959
[TBL] [Abstract][Full Text] [Related]
34. The Significance of MicroRNAs Expression in Regulation of Extracellular Matrix and Other Drug Resistant Genes in Drug Resistant Ovarian Cancer Cell Lines.
Kazmierczak D; Jopek K; Sterzynska K; Ginter-Matuszewska B; Nowicki M; Rucinski M; Januchowski R
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32283808
[TBL] [Abstract][Full Text] [Related]
35. Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance.
Van Hattum AH; Schlüper HM; Hausheer FH; Pinedo HM; Boven E
Int J Cancer; 2002 Jul; 100(1):22-9. PubMed ID: 12115582
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
37. Frequent promoter hypermethylation of TGFBI in epithelial ovarian cancer.
Kang S; Dong SM; Park NH
Gynecol Oncol; 2010 Jul; 118(1):58-63. PubMed ID: 20421128
[TBL] [Abstract][Full Text] [Related]
38. Transforming growth Factor-Beta-Induced Protein (TGFBI)/(βig-H3): a matrix protein with dual functions in ovarian cancer.
Ween MP; Oehler MK; Ricciardelli C
Int J Mol Sci; 2012; 13(8):10461-10477. PubMed ID: 22949874
[TBL] [Abstract][Full Text] [Related]
39. Global gene expression analysis of early response to chemotherapy treatment in ovarian cancer spheroids.
L'Espérance S; Bachvarova M; Tetu B; Mes-Masson AM; Bachvarov D
BMC Genomics; 2008 Feb; 9():99. PubMed ID: 18302766
[TBL] [Abstract][Full Text] [Related]
40. HIF Inactivation of p53 in Ovarian Cancer Can Be Reversed by Topotecan, Restoring Cisplatin and Paclitaxel Sensitivity.
Parmakhtiar B; Burger RA; Kim JH; Fruehauf JP
Mol Cancer Res; 2019 Aug; 17(8):1675-1686. PubMed ID: 31088908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
